NCT05310383 is a Phase 2 clinical trial of Tislelizumab plus radiotherapy in Recurrent Cervical Carcinoma, sponsored by Lei Li.

Who is sponsoring NCT05310383?

NCT05310383 is sponsored by Lei Li.

What drugs are being tested in NCT05310383?

Interventions in NCT05310383: Tislelizumab plus radiotherapy.

What condition does NCT05310383 study?

NCT05310383 studies Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy, Immunotherapy, Anti-programmed Cell Death Receptor 1, Immune Checkpoint Inhibitors, Tislelizumab, Objective Response Rate, Survival Outcomes.

Is NCT05310383 still recruiting?

NCT05310383 is currently status unknown. Last updated 11 April 2022.

Last reviewed 2022-04-11 · How we verify

NCT05310383

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Status unknown Phase 2 Last updated 11 April 2022

What this trial tests

Phase 2 trial testing Tislelizumab plus radiotherapy in Recurrent Cervical Carcinoma in 58 participants. Status unknown.

Timeline

27 March 2022

Primary endpoint
27 March 2023

27 March 2024

Quick facts

Lead sponsor	Lei Li
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	27 March 2022
Primary completion	27 March 2023
Estimated completion	27 March 2024
Sites	1 location across China

Drugs / interventions tested

Tislelizumab plus radiotherapy

Conditions studied

Recurrent Cervical Carcinoma — all drugs for Recurrent Cervical Carcinoma →
Metastatic Cervical Carcinoma — all drugs for Metastatic Cervical Carcinoma →
Persistent Cervical Carcinoma — all drugs for Persistent Cervical Carcinoma →
Radiotherapy — all drugs for Radiotherapy →

Sponsor

Lei Li — full company profile →

Who can join

18 and older, female only, with Recurrent Cervical Carcinoma or Metastatic Cervical Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. Patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. They will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles. Treatment continue until disease progression, intolerable toxicity, or patient refusal. Objective response rates primary objective. Progression-free survival, overall survival, and safety are secondary objectives. The study will enroll a total of 50 patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors in cervical cancer: Current status and research progress.
Xie Y, Kong W, Zhao X, Zhang H, et al · · 2022 · cited 28× · PMID 36387196 · DOI 10.3389/fonc.2022.984896
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L, Moreau Bachelard C, Renaud E, Dhamelincourt E, et al · · 2023 · cited 6× · PMID 37539054 · DOI 10.3389/fimmu.2023.1201675
Bridging the Gap: Immune Checkpoint Inhibitor as an Option in the Management of Advanced and Recurrent Cervical Cancer in Sub-Saharan Africa.
Okpalanwaka IF, Anazodo FI, Chike-Aliozor ZL, Ekweozor C, et al · · 2024 · cited 2× · PMID 39398762 · DOI 10.7759/cureus.69136

Verify or expand the search:

Other recruiting trials for Recurrent Cervical Carcinoma

Currently open trials in the same condition.

NCT06157151 — PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cance · Phase 2 · recruiting
NCT06238635 — Dostarlimab and Cobolimab in Advanced Cervical Cancer · Phase 2 · active not recruiting
NCT04574635 — Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer · active not recruiting
NCT03968406 — Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers · Phase 1 · recruiting
NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M · Phase 2 · active not recruiting

Other Lei Li trials

Trials by the same sponsor.

NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
NCT06490380 — HRD Status Reference Standard Based on WGS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05310383 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lei Li
Last refreshed: 11 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05310383.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing